EurekaBio
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $40M
Overview
A Chinese biotech company providing innovative viral vector and automated cell therapy manufacturing platforms to enable and reduce costs for CGT developers.
Oncology
Technology Platform
The EuLV™ System is a stable producer cell line platform for scalable, cost-effective lentiviral vector production, and the CellSep™/EuBioX systems provide automated solutions for cell therapy manufacturing and bioprocess development.
Opportunities
Significant growth opportunity driven by the global expansion of CGT pipelines, particularly in China, and the industry's urgent need for scalable, cost-effective manufacturing solutions for viral vectors and cell processing.
Risk Factors
Technology adoption risk against established and emerging competitors, execution risk in scaling manufacturing and supporting global clients, and dependency on the regulatory and commercial success of its CGT developer customers.
Competitive Landscape
Competes with other CGT enabling technology firms like Lonza, Miltenyi Biotec, and MaxCyte, as well as CDMOs offering vector services. Differentiation lies in its integrated stable cell line system for LVV production and focus on automated, closed-cell processing systems.